The Math Shows FELC Can Go To $37
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Should l Buy BSX?
Source: NASDAQ.COM
ETF Analyst Target Price Insights: The Fidelity Enhanced Large Cap Core ETF (FELC) has an implied analyst target price of $37.23, indicating a potential upside of 12.45% from its current trading price of $33.11.
Notable Holdings with Upside Potential: Key underlying holdings such as Boston Scientific Corp., Nucor Corp., and Cirrus Logic Inc. show significant upside potential, with expected increases of 18.85%, 18.41%, and 18.20% respectively, compared to their recent share prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 63.420
Low
94.00
Averages
108.14
High
132.00
Current: 63.420
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Faces Securities Litigation Warning
- Litigation Investigation: Faruqi & Faruqi LLP is investigating potential claims against Boston Scientific, specifically urging investors who purchased securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Disappointing Performance: Boston Scientific's February 4, 2026, earnings report revealed that U.S. EP sales fell short of expectations, leading to a significant net income miss and disappointing guidance for fiscal 2026, highlighting a stark contrast between management's optimistic market growth claims and the actual performance.
- Stock Price Plunge: Following the disappointing results, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, which directly impacted investors' financial interests and indicated a loss of market confidence in the company's future outlook.
- Legal Rights Reminder: Faruqi & Faruqi encourages affected investors to reach out for information or to participate in the litigation, ensuring their legal rights are protected, while also reminding potential lead plaintiffs that they can apply for lead plaintiff status through their chosen counsel.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Boston Scientific Class Action Lawsuit Notification
- Class Action Initiation: Boston Scientific faces a class action lawsuit for false statements made between July 23, 2025, and February 3, 2026, with investors needing to apply as lead plaintiffs by May 4, 2026, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported a fourth-quarter net income of $672 million, or $0.45 per share, which, despite year-over-year growth, fell short of the expected range of $0.48 to $0.52, leading to a stock price drop of over 17%, reflecting market concerns about its growth outlook.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the U.S. electrophysiology market, which have eroded its market share and limited growth potential, indicating a threat to the company's position in the industry.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, demonstrating its expertise and successful track record in handling such cases.
See More
Boston Scientific Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Boston Scientific, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by May 4, 2026.
- Disappointing Earnings Report: Boston Scientific's Q4 2025 financial results, released on February 4, 2026, revealed lower-than-expected sales in its electrophysiology division and guidance for FY 2026 that fell significantly short of analyst expectations, indicating slow market growth and increased competition.
- Stock Price Plunge: Following the earnings report, Boston Scientific's stock price dropped by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, reflecting market concerns about the company's future outlook.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in securities class litigation, founded over 85 years ago, and has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct.
See More
Boston Scientific Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: On April 16, 2026, shareholders of Boston Scientific (NYSE: BSX) filed a class action lawsuit alleging violations of the Securities Exchange Act of 1934 against the company and certain senior officers for misrepresentations made between July 23, 2025, and February 3, 2026.
- Investor Losses: The lawsuit claims that misleading statements regarding Boston Scientific's U.S. electrophysiology segment led to financial losses for investors during the holding period, which negatively impacts the company's market reputation and shareholder confidence.
- Legal Procedure Details: Investors wishing to serve as lead plaintiffs must file necessary documents by May 4, 2026, with all legal representation on a contingency fee basis, meaning shareholders incur no fees or expenses.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in handling class actions, underscoring its expertise and influence in securities litigation.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record in class actions to ensure effective legal support, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Boston Scientific Faces Securities Litigation Warning
- Litigation Investigation: Faruqi & Faruqi LLP is investigating potential claims against Boston Scientific, specifically urging investors who purchased securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Disappointing Performance: Boston Scientific's February 4, 2026, earnings report revealed that U.S. EP sales fell short of expectations, leading to a significant net income miss and disappointing guidance for fiscal 2026, highlighting a stark contrast between management's optimistic market growth claims and the actual performance.
- Stock Price Plunge: Following the disappointing results, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, which directly impacted investors' financial interests and indicated a loss of market confidence in the company's future outlook.
- Legal Rights Reminder: Faruqi & Faruqi encourages affected investors to reach out for information or to participate in the litigation, ensuring their legal rights are protected, while also reminding potential lead plaintiffs that they can apply for lead plaintiff status through their chosen counsel.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Boston Scientific Class Action Lawsuit Notification
- Class Action Initiation: Boston Scientific faces a class action lawsuit for false statements made between July 23, 2025, and February 3, 2026, with investors needing to apply as lead plaintiffs by May 4, 2026, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported a fourth-quarter net income of $672 million, or $0.45 per share, which, despite year-over-year growth, fell short of the expected range of $0.48 to $0.52, leading to a stock price drop of over 17%, reflecting market concerns about its growth outlook.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the U.S. electrophysiology market, which have eroded its market share and limited growth potential, indicating a threat to the company's position in the industry.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, demonstrating its expertise and successful track record in handling such cases.
See More
Boston Scientific Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Boston Scientific, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by May 4, 2026.
- Disappointing Earnings Report: Boston Scientific's Q4 2025 financial results, released on February 4, 2026, revealed lower-than-expected sales in its electrophysiology division and guidance for FY 2026 that fell significantly short of analyst expectations, indicating slow market growth and increased competition.
- Stock Price Plunge: Following the earnings report, Boston Scientific's stock price dropped by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, reflecting market concerns about the company's future outlook.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in securities class litigation, founded over 85 years ago, and has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct.
See More
Boston Scientific Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: On April 16, 2026, shareholders of Boston Scientific (NYSE: BSX) filed a class action lawsuit alleging violations of the Securities Exchange Act of 1934 against the company and certain senior officers for misrepresentations made between July 23, 2025, and February 3, 2026.
- Investor Losses: The lawsuit claims that misleading statements regarding Boston Scientific's U.S. electrophysiology segment led to financial losses for investors during the holding period, which negatively impacts the company's market reputation and shareholder confidence.
- Legal Procedure Details: Investors wishing to serve as lead plaintiffs must file necessary documents by May 4, 2026, with all legal representation on a contingency fee basis, meaning shareholders incur no fees or expenses.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in handling class actions, underscoring its expertise and influence in securities litigation.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record in class actions to ensure effective legal support, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
